43.1 – 2020 Year in Review: Advances in Fatty Liver Disease Drugs and Diagnostics

Vlad Ratziu discusses a "boiling hot" field of emerging NASH drugs and "particularly rich" data coming from no-invasive diagnostic testing

Despite elafibranor failing, obeticholic acid not securing FDA approval and COVID-19 related limitations in the conduct of clinical trials, “this was a very good year actually for NASH clinical trials,” with “some significant advances in terms of therapeutics for NASH” and . We had the results of several trials this year. We had the unfolding story of other molecules that are in development for NASH and all this makes for a very, very vibrant environment in terms of therapeutic research for NASH.” Further, MRI-based methods “are becoming mainstream,” starting to fulfill the promise of non-invasive testing.


More about Vlad Ratziu, MD, PhD

Experience Nudge Learning! Interested in a new way of learning?